Federal Supply Schedule 36F79721D0068
Award Date
1/1/21
Last Date to Order
12/31/25
Federal Agency
Veterans Integrated Service Network 12
Awardee
Urogen Pharma Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Urogen Pharma Inc. The BPA has a potential value of $1.5 million and expires on February 3, 2021. It was established on October 2, 2020 to procure Jelmyto, a treatment for low-grade upper tract urothelial cancer. As the sole awardee, Urogen Pharma will provide its product Jelmyto to the VA National Acquisition Center through this BPA. Jelmyto is an FDA-approved medication for the...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the U.S. Department of Veterans Affairs (VA) to Urogen Pharma Inc., a pharmaceutical company specializing in the drug JELMYTO. The single-award BPA, valued at up to $2.5 million, was made under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is valid through February 2026. The purpose of this BPA is to provide the VA with a streamlined procurement vehicle to order JELMYTO, a drug used to...
The Department of Veterans Affairs (VA) has awarded Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This contract, valid through August 2029, enables the VA and its Veterans Integrated Service Networks (VISNs) to efficiently procure a variety of oncology and specialty medications to support comprehensive healthcare services for veteran patients nationwide. Under...
The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady...
The U.S. Department of Veterans Affairs (VA) has awarded a $198 million Federal Supply Schedule (FSS) contract and a $50 million Blanket Purchase Agreement (BPA) to United Therapeutics Corporation, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods. These Indefinite Delivery Vehicles (IDVs) allow the VA to efficiently procure United Therapeutics' specialized drug portfolio, including treatments for pulmonary arterial hypertension and certain types of cancer,...
The U.S. Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $5.96 million BPA, with a period of performance through March 2026, enables the VA to procure the drug Adstiladrin (nadofaragene firadenovec), a treatment for genitourinary cancers, to support the provision of healthcare services to...
The Department of Veterans Affairs (VA) has awarded Janssen Products LP, a subsidiary of Johnson & Johnson, a multiple-award Federal Supply Schedule (FSS-61-IB) contract with a ceiling value of $881,313,820 through July 2025. This contract enables the VA's regional Veterans Integrated Service Networks (VISNs) to place delivery orders for pharmaceutical products, primarily the antitubercular medication Sirturo (bedaquiline) and the oncology drug Balversa (erdafitinib). The VA has also awarded...
The U.S. Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract to Telix Pharmaceuticals US Inc., a global biopharmaceutical company, to provide radiopharmaceutical products for nuclear medicine and medical imaging services. The $225,000 multiple-award contract has an ultimate completion date of August 2027 and falls under FSS 65 I B for drugs, pharmaceuticals, and related products. Under this FSS contract, the VA has issued several firm fixed-price delivery...
The federal contract IDV award is a Blanket Purchase Agreement (BPA) between the U.S. Department of Veterans Affairs (VA) and Otsuka America Pharmaceutical Inc., a pharmaceutical manufacturer. The $15 million BPA, awarded in March 2020, is specifically for the delivery of Jynarque (tolvaptan), a medication used to treat autosomal dominant polycystic kidney disease and hyponatremia in VA patients. This BPA, along with a $396 million Federal Supply Schedule (FSS) contract under the Pharmaceuticals...
This is a $2,616,322.00 Indefinite Delivery Contract (IDC) awarded by the U.S. Department of Veterans Affairs (VA), specifically through Veterans Integrated Service Network (VISN) 9, to Pharmalogic Holdings Corp. (doing business as Pharmalogic Puerto Rico). The contract is for the delivery of PYLARIFY F-18 piflufolastat, a radiopharmaceutical used for prostate cancer imaging, to support the VA's nuclear medicine services and imaging programs for veterans. The contract has a 5-year performance...